CT 2500
Alternative Names: CT-2500Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Circadian Therapeutics
- Class Antidementias; Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease in United Kingdom
- 28 Nov 2024 No recent reports of development identified for phase-I development in Parkinson's-disease in United Kingdom
- 14 Oct 2021 Phase I trials in Alzheimer's disease in United Kingdom (Circadian Therapeutics website, October 2021)